December 16, 2025 08:00 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Goa nightclub fire horror: Luthra brothers brought back to India from Thailand, arrested | Messi chaos costs minister his job: Aroop Biswas resigns after Salt Lake Stadium fiasco | Bengal SIR draft list out: Around 58 lakh voters’ names dropped | Relief for Sonia, Rahul Gandhi as Delhi court refuses to act on ED chargesheet in National Herald case | Centre moves to replace MGNREGA with 'G Ram G', sets stage for winter session showdown | Messi surrounded by VIPs, fans rage: Five held in stadium vandalism case | 'Messi was uncomfortable, lost his cool!': Ex-India footballer reveals what really happened at chaotic Kolkata stadium | PM Modi embarks on historic three-nation visit to Jordan, Ethiopia, and Oman | Caught in Thailand! Fugitive Goa nightclub owners detained after deadly fire kills 25 | After Putin’s blockbuster Delhi visit, Modi set to host German Chancellor Friedrich Merz in January
Image: UNI

MSN Labs launches Posaconazole (PosaOne) to treat Black fungus

| @indiablooms | May 22, 2021, at 12:21 am

Kolkata/IBNS: The drug-maker enterprise MSN Laboratories Pvt. Ltd. (MSN), introduced Posaconazole in India, under the brand name PosaOne, which is a triazole antifungal agent indicated for treating mucormycosis patients.

PosaOne contains both 100 mg delayed-release tablets & 300 mg injections. While the price of the tablet is Rs 600, the injections cost's a staggering Rs 8,500, according to The Hindu.

Many patients recovering from Covid 19 have been detected with a rare and deadly fungal infection known as mucormycosis or Black fungus. With mortality rates on the rise, accessibility of anti-fungal medication is being an unmet deficit in these testing times, MSN told.

The company officials mentioned that due to MSN’s competence in research and manufacturing of antifungal infection drugs, it is now targeting proactively to reach patients across India by ensuring the access of  PosaOne, through its distribution network & field force.

MSN has also developed the active pharmaceutical ingredient and the formulation of PosaOne in its in-house R&D and manufacturing units, company personnel informed, while also stating that the drug is approved by the Drug Controller General of India (DGCI) and matches the international quality standards.

As part of the COVID treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200mg, 400mg & 800mg, OSELOW (Oseltamivir) as 75 mg capsules, recently, it also licensed Baridoz (Baricitinib) with Eli Lilly, MSN stated.

For availability of all COVID Drugs from MSN, patients can contact MSN COVID Helpline @ 91005 91030 or email customercare@msnlabs.com for further assistance.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.